The estimated Net Worth of Aron Marc Knickerbocker is at least $9.6 Milhão dollars as of 7 June 2019. Aron Knickerbocker owns over 11,357 units of Five Prime Therapeutics Inc stock worth over $9,595,572 and over the last 10 years Aron sold FPRX stock worth over $0.
Sign up
Aron Knickerbocker FPRX stock SEC Form 4 insiders trading
Aron has made over 24 trades of the Five Prime Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Aron exercised 11,357 units of FPRX stock worth $62,918 on 7 June 2019.
The largest trade Aron's ever made was exercising 38,084 units of Five Prime Therapeutics Inc stock on 24 June 2015 worth over $327,142. On average, Aron trades about 2,620 units every 35 days since 2014. As of 7 June 2019 Aron still owns at least 195,828 units of Five Prime Therapeutics Inc stock.
You can see the complete history of Aron Knickerbocker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Aron Knickerbocker's mailing address?
Aron's mailing address filed with the SEC is 2 Corporate Dr, South San Francisco, CA 94080, USA.
Insiders trading at Five Prime Therapeutics Inc
Over the last 11 years, insiders at Five Prime Therapeutics Inc have traded over $158,392,438 worth of Five Prime Therapeutics Inc stock and bought 4,750,507 units worth $20,970,721 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., eCapital Partners Gp, L.L.C..... On average, Five Prime Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $6,730,346. The most recent stock trade was executed by Francis Willard Sarena on 11 December 2020, trading 22,000 units of FPRX stock currently worth $1,078,000.
What does Five Prime Therapeutics Inc's logo look like?
Complete history of Aron Knickerbocker stock trades at Five Prime Therapeutics Inc
Five Prime Therapeutics Inc executives and stock owners
Five Prime Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Peder Jensen,
Director -
Sheila Gujrathi,
Director -
Mark Mcdade,
Director -
Kapil Dhingra,
Director -
Fred E Cohen,
Director -
Garry A Nicholson,
Director -
Franklin M Berger,
Director -
Robert Steven Sikorski,
SVP and Chief Medical Officer -
Luis Borges,
SVP, Research -
Kevin Paul Baker,
SVP, Development Sciences -
Marc Belsky,
SVP and CFO -
R Lee Douglas,
Director -
Francis Willard Sarena,
Chief Strategy Officer -
Aron Marc Knickerbocker,
President & CEO -
David V Smith,
Executive Vice President & CFO -
Lewis T Williams,
Director -
David White,
See Remarks -
Carol Schafer,
Director -
Partners L P/Ilbiotechnolog...,
-
Bryan Irving,
EVP, Chief Scientific Officer -
Capital Partners Gp, L.L.C....,
-
Julie Hambleton,
SVP & Chief Medical Officer -
William Michael Kavanaugh,
SVP & Chief Scientific Officer -
Brian G Atwood,
Director -
Lori Lyons Williams,
Director -
Helen Louise Collins,
EVP and Chief Medical Officer -
William R Ringo,
Director -
Thomas Civik,
President and CEO -
Partners L P/Ilbiotechnolog...,